Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
Lung cancer is the leading cause of cancer-related deaths globally, accounting for 1.8 million fatalities in 2020. Genetic mutations, chromosomal abnormalities, transcription factors, mutations in tumor suppressor genes, and mutations in oncogenes have all been associated with an increased risk of L...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | All Life |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/26895293.2024.2417192 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593470903025664 |
|---|---|
| author | Saloni Mangal Abhijit Debnath Rupa Mazumder Avijit Mazumder Rajesh Kumar Singh Jahanvi Sanchitra S.K. Asif Jan Pratibha Pandey Bimlesh Kumar Anil Kumar Singh |
| author_facet | Saloni Mangal Abhijit Debnath Rupa Mazumder Avijit Mazumder Rajesh Kumar Singh Jahanvi Sanchitra S.K. Asif Jan Pratibha Pandey Bimlesh Kumar Anil Kumar Singh |
| author_sort | Saloni Mangal |
| collection | DOAJ |
| description | Lung cancer is the leading cause of cancer-related deaths globally, accounting for 1.8 million fatalities in 2020. Genetic mutations, chromosomal abnormalities, transcription factors, mutations in tumor suppressor genes, and mutations in oncogenes have all been associated with an increased risk of LC development. Heterogeneity of the disease, resistance to chemotherapy, and side effects such as nausea and vomiting, fatigue, anemia, neuropathy, hair loss, and skin and nail changes are associated with conventional therapeutics such as chemotherapy, radiation therapy, and targeted therapy. Thus, the treatment of the disease urgently requires the discovery of novel therapeutic approaches. This review identifies and discusses key molecular and genetic targets for LC therapy, highlighting recent advancements and potential clinical applications. Our efforts encompass all biological targets and aim to increase our understanding of these processes to better comprehend the disease's molecular mechanisms and develop new drugs and more effective LC treatments. |
| format | Article |
| id | doaj-art-5cebcf123ae34675b6b9d8612aa32850 |
| institution | Kabale University |
| issn | 2689-5307 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | All Life |
| spelling | doaj-art-5cebcf123ae34675b6b9d8612aa328502025-01-20T14:38:00ZengTaylor & Francis GroupAll Life2689-53072024-12-01170110.1080/26895293.2024.24171922417192Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomesSaloni Mangal0Abhijit Debnath1Rupa Mazumder2Avijit Mazumder3Rajesh Kumar Singh4Jahanvi Sanchitra5S.K. Asif Jan6Pratibha Pandey7Bimlesh Kumar8Anil Kumar Singh9Noida Institute of Engineering and Technology (Pharmacy Institute)Noida Institute of Engineering and Technology (Pharmacy Institute)Noida Institute of Engineering and Technology (Pharmacy Institute)Noida Institute of Engineering and Technology (Pharmacy Institute)Banaras Hindu UniversityNoida Institute of Engineering and Technology (Pharmacy Institute)Noida Institute of Engineering and Technology (Pharmacy Institute)Noida Institute of Engineering and TechnologyLovely Professional UniversityBanaras Hindu UniversityLung cancer is the leading cause of cancer-related deaths globally, accounting for 1.8 million fatalities in 2020. Genetic mutations, chromosomal abnormalities, transcription factors, mutations in tumor suppressor genes, and mutations in oncogenes have all been associated with an increased risk of LC development. Heterogeneity of the disease, resistance to chemotherapy, and side effects such as nausea and vomiting, fatigue, anemia, neuropathy, hair loss, and skin and nail changes are associated with conventional therapeutics such as chemotherapy, radiation therapy, and targeted therapy. Thus, the treatment of the disease urgently requires the discovery of novel therapeutic approaches. This review identifies and discusses key molecular and genetic targets for LC therapy, highlighting recent advancements and potential clinical applications. Our efforts encompass all biological targets and aim to increase our understanding of these processes to better comprehend the disease's molecular mechanisms and develop new drugs and more effective LC treatments.http://dx.doi.org/10.1080/26895293.2024.2417192lung cancerlung cancer drug targetssmall cell carcinomanon-small cell carcinomalung cancer drugs |
| spellingShingle | Saloni Mangal Abhijit Debnath Rupa Mazumder Avijit Mazumder Rajesh Kumar Singh Jahanvi Sanchitra S.K. Asif Jan Pratibha Pandey Bimlesh Kumar Anil Kumar Singh Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes All Life lung cancer lung cancer drug targets small cell carcinoma non-small cell carcinoma lung cancer drugs |
| title | Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes |
| title_full | Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes |
| title_fullStr | Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes |
| title_full_unstemmed | Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes |
| title_short | Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes |
| title_sort | molecular landscape of lung cancer insights into therapeutic targets and clinical outcomes |
| topic | lung cancer lung cancer drug targets small cell carcinoma non-small cell carcinoma lung cancer drugs |
| url | http://dx.doi.org/10.1080/26895293.2024.2417192 |
| work_keys_str_mv | AT salonimangal molecularlandscapeoflungcancerinsightsintotherapeutictargetsandclinicaloutcomes AT abhijitdebnath molecularlandscapeoflungcancerinsightsintotherapeutictargetsandclinicaloutcomes AT rupamazumder molecularlandscapeoflungcancerinsightsintotherapeutictargetsandclinicaloutcomes AT avijitmazumder molecularlandscapeoflungcancerinsightsintotherapeutictargetsandclinicaloutcomes AT rajeshkumarsingh molecularlandscapeoflungcancerinsightsintotherapeutictargetsandclinicaloutcomes AT jahanvisanchitra molecularlandscapeoflungcancerinsightsintotherapeutictargetsandclinicaloutcomes AT skasifjan molecularlandscapeoflungcancerinsightsintotherapeutictargetsandclinicaloutcomes AT pratibhapandey molecularlandscapeoflungcancerinsightsintotherapeutictargetsandclinicaloutcomes AT bimleshkumar molecularlandscapeoflungcancerinsightsintotherapeutictargetsandclinicaloutcomes AT anilkumarsingh molecularlandscapeoflungcancerinsightsintotherapeutictargetsandclinicaloutcomes |